I A Lampert

Publications (4)13.53 Total impact

• Article: The significance of tumour cell immunophenotype in myeloma and its impact on clinical outcome.

  N-T Ngo, C Brodie, C Giles, D Horncastle, M Klammer, I A Lampert, A Rahemtulla, K N Naresh
  [show abstract] [hide abstract]
  ABSTRACT: Antigen expression of multiple myeloma (MM) cells is heterogeneous. We have investigated the clinical impact of expression of some of the commonly used immunohistochemical markers in the diagnostic work-up of bone marrow trephine biopsy (BMTB) samples in MM. BMTB samples from 107 MM patients who had received an autologous stem cell transplant (ASCT) following chemotherapy were evaluated. In 75 cases, the immunophenotype had been evaluated on two or more occasions on further follow-up. In the cases evaluated, 32%, 79%, 73%, 39% and 60% of cases had been scored positive for CD20, CD79a, CD56, cyclin D1 and epithelial membrane antigen (EMA) respectively. Absence of CD79a was predictive of poor overall survival (OS) from the time of transplant (p = 0.029) and poor event-free survival (EFS) from the time of transplant (p = 0.003). Absence of EMA (p = 0.02) was predictive of poor EFS from the time of diagnosis. Presence of CD56 was predictive of poor EFS from the time of diagnosis (p = 0.026). On multivariate analysis, only CD79a expression (OS and EFS from the time of transplant) and EMA expression (EFS from the time of diagnosis) maintained their significance. 13 of 75 patients showed an immunophenotypic drift during the disease course. Loss of CD20 (four cases) during the disease course in cases that were previously scored positive correlated with significant worsening both, of OS (p = 0.02) and EFS (p = 0.009) from the time of diagnosis. Immunophenotype impacts on clinical outcome in MM.
  Journal of clinical pathology 11/2009; 62(11):1009-15. · 2.43 Impact Factor
• Article: Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.

  V Elliot, D Marin, D Horncastle, K Elderfield, J Howard, J F Apperley, I A Lampert, K N Naresh
  Histopathology 06/2007; 50(6):810-2. · 3.08 Impact Factor
• Article: Burkitt lymphoma and Leishmaniasis in the same tissue sample in an AIDS patient.

  N Boutros, D Hawkins, M Nelson, I A Lampert, K N Naresh
  Histopathology 07/2006; 48(7):880-1. · 3.08 Impact Factor
• Article: Percentage of CD34 cells in a minimum 500-cell count in bone marrow trephines of patients with chronic myeloid leukaemia provides the best correlation with aspirate blast count.

  V Elliot, D Marin, D Horncastle, K Elderfield, J F Apperley, I A Lampert, K Naresh
  British Journal of Haematology 09/2005; 130(3):460-1. · 4.94 Impact Factor